Tryngolza (Olezarsen): Mechanism of Action and Benefits
Tryngolza (olezarsen) is an antisense oligonucleotide that binds to apolipoprotein C-III (apoC-III) mRNA, causing its degradation and reducing apoC-III protein levels, which in turn dramatically lowers triglycerides by 50-70% and significantly reduces acute pancreatitis risk in patients with severe hypertriglyceridemia. 1
Mechanism of Action
Olezarsen is a GalNAc₃-conjugated antisense oligonucleotide (ASO) with a highly targeted mechanism 1:
- Binds to apoC-III mRNA in hepatocytes, leading to mRNA degradation
- Reduces serum apoC-III protein by 60-80% at therapeutic doses
- Increases clearance of triglyceride-rich lipoproteins (chylomicrons and VLDL) through both lipoprotein lipase-dependent and -independent pathways
- GalNAc₃ conjugation enables specific hepatocyte targeting via asialoglycoprotein receptors, allowing lower dosing and reduced injection frequency compared to earlier antisense therapies
The drug is administered subcutaneously at 80 mg monthly for familial chylomicronemia syndrome (FCS) or 50-80 mg monthly for severe hypertriglyceridemia, with peak concentrations reached in approximately 2 hours and a terminal half-life of 4 weeks 1.
Clinical Benefits
Triglyceride Reduction
The most robust benefit is profound triglyceride lowering 2, 3:
- FCS patients: 43.5% reduction at 6 months with 80 mg dose (placebo-adjusted)
- Severe hypertriglyceridemia: 49-72% reduction depending on dose and trial
- Moderate hypertriglyceridemia: 49-53% reduction with monthly dosing
Pancreatitis Prevention
This is the most clinically meaningful outcome for morbidity and mortality 2, 3:
- 88% reduction in acute pancreatitis events in FCS patients (rate ratio 0.12; 95% CI 0.02-0.66)
- 85% reduction in severe hypertriglyceridemia trials (rate ratio 0.15; 95% CI 0.05-0.40, p<0.001)
- In the BALANCE trial, only 1 pancreatitis episode occurred in each olezarsen group versus 11 in placebo by 53 weeks
Additional Lipid Benefits
Beyond triglycerides, olezarsen improves the atherogenic lipid profile 3, 4:
- ApoC-III reduction: 65-80% decrease
- Non-HDL cholesterol: 18-25% reduction
- ApoB reduction: 10-12% decrease
- HDL cholesterol increase: 22-35% improvement
- Remnant cholesterol: Significant reduction
- LDL cholesterol: Minimal change or modest increase (17% in some trials)
Anti-Inflammatory Effects
Recent mechanistic data shows olezarsen reduces postprandial lipid-driven inflammation 5:
- 25% reduction in monocyte lipid droplet accumulation after fat loading
- Decreased expression of monocyte activation markers (CD11c, CD11b, CD16)
- 14% reduction in monocyte adhesion and transendothelial migration ex vivo
- Lower IL-1β gene expression in monocytes
Safety Profile
The drug demonstrates a favorable safety profile in completed trials 2, 3, 6:
- Overall adverse events comparable to placebo
- Most common: mild injection site reactions
- No clinically significant thrombocytopenia (unlike earlier ASO therapies)
- Dose-dependent considerations with 80 mg dose:
- Increased liver enzyme elevations ≥3× ULN (RR 2.56)
- Dose-dependent increase in hepatic fat fraction
- More frequent ALT/AST elevations
Important caveat: The 50 mg dose provides substantial efficacy with potentially better hepatic tolerability, making it preferable for severe hypertriglyceridemia when the 80 mg dose is not specifically required 3.
Clinical Context
Olezarsen represents a precision medicine advance for patients who remain at high risk despite standard therapy 7, 8. The GalNAc₃ conjugation technology enables:
- Lower dosing requirements
- Reduced injection volume
- Monthly (rather than weekly) administration
- Improved hepatocyte specificity
- Better tolerability than first-generation antisense therapies
The primary indication is preventing life-threatening acute pancreatitis in FCS and severe hypertriglyceridemia, where the dramatic reduction in pancreatitis events represents a major improvement in morbidity and quality of life 2, 3. Long-term cardiovascular outcomes trials are ongoing to determine whether triglyceride lowering translates to reduced cardiovascular events 9.